{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.27","value":"-1.16"},{"groupId":"OG001","spread":"1.23","value":"-1.89"},{"groupId":"OG002","spread":"1.16","value":"-1.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"226"},{"groupId":"OG002","value":"221"}],"units":"Participants"}],"description":"DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), Erythrocyte Sedimentation Rate (ESR) (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\\*square root (sqrt)(TJC28)+0.28\\*sqrt(SJC28)+0.70\\*natural log(ESR)+0.014\\*Patient's Global VAS. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (DAS28-ESR)","type":"SECONDARY","unitOfMeasure":"units on a scale"}